DOCSLIB.ORG

Inborn Errors of Metabolism: Disorder of Adults?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inborn Errors of Metabolism: Disorder of Adults? Section 18 Metabolic Disorders Chapter 135 Inborn Errors of Metabolism: Disorder of Adults? Kothiwale VA, Varun Kumar B INTRODUCTION Group 1 Inborn errors of metabolism (IEMs) are individually rare, but It involves cellular organelles and includes lysosomal, peroxisomal, collectively numerous. The term was coined by Archibald Garrod, glycosylation and cholesterol synthesis defects. who in 1927 presented the Huxley lecture at Charing Cross Hospital.1 • Mucopolysaccharidosis (Hurler, Hunter, Sanfilippo, Morquio, Until recently, IEMs were considered a specialty of pediatricians. Maroteaux, Sly, etc.) Indeed, the term “inborn” has meant for a long time, a disease which • Sphingolipidosis (gangliodosis, Tay-Sachs, Sandhoff) starts in the newborn period or at least in childhood. Although • Lactosylceramidosis (Gaucher, Farber, Niemann-Pick, Krabbe, most IEMs can have mild forms starting in adolescence or late in sulfatase deficiency) adulthood, this concept of “adult onset IEMs” has not reached the • Glycoproteinases (fucosidosis, manosidosis, sialidosis, aspartyl- medical community until recently. glucosaminuria) They refer to single gene disorders wherein loss of function of a • Defects in membrane transport (cystinosis, succinic semialdehyde single enzyme results in abnormalities in synthesis or catabolism dehydrogenase, Salla disease) of proteins, carbohydrates or fats, which results in a disruption in a • Peroxisomal biogenesis defects (Zellweger syndrome, adreno- metabolic pathway. This results in toxic accumulations of substrates leukodystrophy, Refsum’s disease, hyperoxaluria Type I) before the disruption, intermediates from alternative pathways, • Fabry’s disease, Shindler, Canavan disease, Pompe disease, acid and/or defects in energy production and utilization. Nearly every lipase deficiency, acid maltase deficiency, cerebrotendinous metabolic disease has several forms that vary in age of onset, clinical xanthomatosis, Juvenile Batten’s disease, Kuf’s disease, etc. severity and mode of inheritance. The mode of inheritance determines the male to female ratio of Group 2 affected and many IEMs have multiple forms that differ in their mode It includes IEMs that give rise to an acute or chronic intoxication. of inheritance. • Disorders of amino acids: Cystinuria, phenylketonuria (PKU), tyrosinemia, homocystinuria, alcaptonuria, maple syrup urine CLASSIFICATION disease, Hartnup’s disease, hyperornithinemia with gyrate A simple method classifies IEMs into disorders involving protein atrophy metabolism, carbohydrate metabolism, lysosomal storage, fatty acid • Organic acidurias: Beta-ketothiolase deficiency, methyl- oxidation defects, mitochondrial disorders, peroxisomal disorders. glutaconic academia, isovaleric academia, glutaric academia A detailed and widely used classification which categorizes IEMs Type I, propionic academia, multiple car boxylase deficiency, from a pathophysiological perspective is as follows (Flow chart 1):2 methyl malonic academia Flow chart 1: Classification of IEMs Metabolic Disorders Section 18 • Urea cycle defects: Citrullinemia, argininemia, argino succinic Group II aciduria, carbomyl phosphate synthase deficiency, ornithine They do not interfere with the embryofetal development and transcarbamylase deficiency they present with a symptom-free interval and clinical signs of • Sugar intolerance: Galactosemia, epimerase deficiency, heredi- “intoxication”, which may be acute (vomiting, coma, liver failure, tary fructose intolerance, galactokinase deficiency thromboembolic complications etc.) or chronic (failure to thrive, • Others: Porphyrias, Wilson’s disease, aceruloplasminemia, developmental delay, ectopia lentis, cardiomyopathy etc.). Circum- Lesch-Nyhan syndrome, Sjogren-Larsson syndrome. stances that can provoke acute metabolic attacks include fever, intercurrent illness and food intake. Clinical expression is often both Group 3 late in onset and intermittent. It includes IEMs that affect the cytoplasmic and mitochondrial energetic processes. Mitochondrial defects are the most severe and Group III are generally untreatable (except ketone body defects and coenzyme Common symptoms in this group include hypoglycemia, hyper- q10 defects). Cytoplasmic energy defects are generally less severe. lactatemia, hepatomegaly, hypotonia, myopathy, car diomyopathy, • Fatty acid oxidation defects: carnitine palmitoyl trans ferase I, cardiac failure, circulatory collapse, and brain involvement. Some II deficiency, short-chain acyl-CoA dehydrogenase deficiency, of the mitochondrial disorders and pentose phosphate pathway medium-chain acyl-CoA dehydrogenase defi ciency, very defects can interfere with the embryofetal development and give rise long chain acyl CoA dehydrogenase deficiency, long-chain to dysmorphism, dysplasia and malformations. 3-hydroxyacyl-CoA dehydrogenase deficiency, glutaric academia In general, clinicians should consider the possibility of an IEM in Type II, carnitine uptake deficiency, hy droxymethylglutaryl CoA any patient with an unexplained neurological disorder. Some brain lyase regions like basal ganglia are highly vulnerable to energy metabolism • Mitochondrial disorders: pyruvate dehydrogenase com plex defects and metals. In an adult patient with an unexplained deficiency, pyruvate carboxylase deficiency, myoclonic epilepsy encephalopathy or an unexplained coma, certain features are highly with ragged red fibers, mitochondrial encephalopathy with suggestive of an IEM: (1) when the encephalopathy is triggered by an lactic acidosis and stroke, phospho enolpyruvate carboxykinase extrinsic factor—surgery, fasting, exercise, treatments, high-protein deficiency, Leber’s hereditary optic atrophy, neuropathy ataxia intake, new medication (Table 1), etc.; and (2) when specific brain and retinitis pigmentosa (NARP) lesions are present on brain magnetic resonance imaging (MRI). • Glycogen storage disorders: von Gierke’s disease (Type I), Two main groups of IEMs are responsible for encephalopathies Pompe’s disease (Type II), Cori’s or Forbes’ disease (Type III), in adults: intoxications (mainly, urea cycle disorders, homocysteine Anderson’s disease (Type IV), McArdle’s disease (Type V), Her’s remethylation defects and acute porphyrias) and energy metabolism disease (Type VI), Tarui’s disease (Type VII), Type IX, Fanconi defects (respiratory chain disorders, pyruvate dehydrogenase Bickel syndrome (Type XI), red cell aldolase deficiency (Type deficiency and biotine responsive basal ganglia disease). XII), Type XIII, Type 0. In the first group, MRI is usually normal or can show poorly specific features whereas in the second group, MRI is almost always CLINICAL MANIFESTATIONS abnormal, showing bilateral lesions of basal ganglia (Leigh syndrome) Inborn errors of metabolism (IEMs) can affect any organ system and or pseudo-strokes (mainly in the case of respiratory chain defects). manifestations vary from those of acute life-threatening disease to subacute progressive degenerative disorder. Progression may be DIAGNOSIS AND MANAGEMENT unrelenting with rapid life-threatening deterioration over hours, Inborn errors of metabolism may present in adolescence or adulthood episodic with intermittent decompensations and asymptomatic as a psychiatric disorder. In some instances, an IEM is suspected intervals, or insidious with slow degeneration over decades. All because of informative family history or because psychiatric three groups of IEMs can manifest in adults, more so with Group I symptoms form part of a more diffuse clinical picture with systemic, disorders. cognitive or motor neurological signs. In neonates and children, manifestations are nonspecific and There are 3 important steps in the diagnosis and management of very similar to that of septicemia, a major reason why IEMs go an IEM. undetected. There may be dysmorphic features present at birth (generally when fetal energy is affected), or develop during the first 1. Suspicion year of life (lysosomal disorders). The symptoms and signs for an IEM are very common and nonspecific; In adults, the symptoms may include mild-to-profound mental therefore, one should think of IEM as an etiology in unexplained/ retardation, autism, learning disorders, behavioral disturbances, peculiar cases and try to rule out the possibility. muscle weakness, progressive paraparesis, hemiparesis, dystonia, chorea, ataxia, ophthalmoplegia, visual deficit, epileptic crisis, hepatosplenomegaly and hypoglycemia. TABLE 1 │ Drugs which aggravate inborn errors of metabolism Some manifestations may be intermittent, precipitated by the Disease Drugs Mechanism stress of illness, or progressive, with worsening over time. Disorders Urea cycle disorders Valproate Blockage of urea cycle manifested by subtle neurologic or psychiatric features often go undiagnosed until adulthood. Porphyrias Imipramine, Porphyrogenic meprobamate Group I Wilson’s disease Neuroleptics Blockage of D2 dopamine receptors Onset in adulthood (upto > 70 years). Among the organs impacted, the nervous system is by far most common. Thus, late onset forms GM2 gangliosidosis Tricyclic ?Increased lipid storage of IEMs often display psychiatric or neurological presentations. antidepressants, phenothiazines These include atypical psychosis or depression, unexplained coma, peripheral neuropathy, cerebellar ataxia, spastic paraparesis, Respiratory chain Valproate Blocks the respiratory dementia, movement disorders, epilepsy, etc. disorders chain 614 Section 18 Chapter 135 Inborn Errors of Metabolism: Disorder of Adults? 2.
Load more

Recommended publications
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • Sialic Acid Storage Disease
    Sialic acid storage disease Description Sialic acid storage disease is an inherited disorder that primarily affects the nervous system. People with sialic acid storage disease have signs and symptoms that may vary widely in severity. This disorder is generally classified into one of three forms: infantile free sialic acid storage disease, Salla disease, and intermediate severe Salla disease. Infantile free sialic acid storage disease (ISSD) is the most severe form of this disorder. Babies with this condition have severe developmental delay, weak muscle tone ( hypotonia), and failure to gain weight and grow at the expected rate (failure to thrive). They may have unusual facial features that are often described as "coarse," seizures, bone malformations, an enlarged liver and spleen (hepatosplenomegaly), and an enlarged heart (cardiomegaly). The abdomen may be swollen due to the enlarged organs and an abnormal buildup of fluid in the abdominal cavity (ascites). Affected infants may have a condition called hydrops fetalis in which excess fluid accumulates in the body before birth. Children with this severe form of the condition usually live only into early childhood. Salla disease is a less severe form of sialic acid storage disease. Babies with Salla disease usually begin exhibiting hypotonia during the first year of life and go on to experience progressive neurological problems. Signs and symptoms of Salla disease include intellectual disability and developmental delay, seizures, problems with movement and balance (ataxia), abnormal tensing of the muscles (spasticity), and involuntary slow, sinuous movements of the limbs (athetosis). Individuals with Salla disease usually survive into adulthood. People with intermediate severe Salla disease have signs and symptoms that fall between those of ISSD and Salla disease in severity.
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Neutral Amino Acids in the Urine [5-7]
    "This is a non-final version of an article published in final form in Current Opinion in Nephrology and Hypertension 22.5 (2013): 539-544 ". Epithelial neutral amino acid transporters, lessons from mouse models Stefan Bröer Research School of Biology, Australian National University Author of correspondence: Name: Stefan Bröer Address: Research School of Biology Linnaeus Way 134 Australian National University Canberra, ACT 0200, Australia Telephone number: +61-2-6125-2540 Email address: [email protected] Abstract (200 words max.): Purpose of review: Epithelial neutral amino acid transporters have been identified at the molecular level in recent years. Mouse models have now established the crucial role of these transporters for systemic amino acid homeostasis. The review summarises recent progress in this field. Recent findings: Epithelial neutral amino acid transporters play an important role in the homeostasis of neutral amino acid levels in the body. They are important for the maintenance of body weight, muscle mass and serve as fuels. They also serve a role in providing nutrients to epithelial cells. Changes of plasma amino acid levels are not necessarily correlated to the amino acids appearing in the urine, changes to organ amino acid metabolism need to be taken into account. Summary: Genetic deletion of neutral amino acid transporters provides insight into their role in protein nutrition and homestasis. Keywords: Protein nutrition, intestine, kidney Abbreviations: dss, dextran-sulphate; hpd, high protein diet; nd, normal diet Introduction The majority of epithelial amino acid transporters have been identified in recent years [1-3]. Many of these are expressed in both intestinal and renal epithelia (Fig.
    [Show full text]
  • Centometabolic® COMBINING GENETIC and BIOCHEMICAL TESTING for the FAST and COMPREHENSIVE DIAGNOSTIC of METABOLIC DISORDERS
    CentoMetabolic® COMBINING GENETIC AND BIOCHEMICAL TESTING FOR THE FAST AND COMPREHENSIVE DIAGNOSTIC OF METABOLIC DISORDERS GENE ASSOCIATED DISEASE(S) ABCA1 HDL deficiency, familial, 1; Tangier disease ABCB4 Cholestasis, progressive familial intrahepatic 3 ABCC2 Dubin-Johnson syndrome ABCD1 Adrenoleukodystrophy; Adrenomyeloneuropathy, adult ABCD4 Methylmalonic aciduria and homocystinuria, cblJ type ABCG5 Sitosterolemia 2 ABCG8 Sitosterolemia 1 ACAT1 Alpha-methylacetoacetic aciduria ADA Adenosine deaminase deficiency AGA Aspartylglucosaminuria AGL Glycogen storage disease IIIa; Glycogen storage disease IIIb AGPS Rhizomelic chondrodysplasia punctata, type 3 AGXT Hyperoxaluria, primary, type 1 ALAD Porphyria, acute hepatic ALAS2 Anemia, sideroblastic, 1; Protoporphyria, erythropoietic, X-linked ALDH4A1 Hyperprolinemia, type II ALDOA Glycogen storage disease XII ALDOB Fructose intolerance, hereditary ALG3 Congenital disorder of glycosylation, type Id ALPL Hypophosphatasia, adult; Hypophosphatasia, childhood; Hypophosphatasia, infantile; Odontohypophosphatasia ANTXR2 Hyaline fibromatosis syndrome APOA2 Hypercholesterolemia, familial, modifier of APOA5 Hyperchylomicronemia, late-onset APOB Hypercholesterolemia, familial, 2 APOC2 Hyperlipoproteinemia, type Ib APOE Sea-blue histiocyte disease; Hyperlipoproteinemia, type III ARG1 Argininemia ARSA Metachromatic leukodystrophy ARSB Mucopolysaccharidosis type VI (Maroteaux-Lamy) 1 GENE ASSOCIATED DISEASE(S) ASAH1 Farber lipogranulomatosis; Spinal muscular atrophy with progressive myoclonic epilepsy
    [Show full text]
  • Table S1. Disease Classification and Disease-Reaction Association
    Table S1. Disease classification and disease-reaction association Disorder class Associated reactions cross Disease Ref[Goh check et al.
    [Show full text]
  • Hartnup Disease
    Hartnup disease Description Hartnup disease is a condition caused by the body's inability to absorb certain protein building blocks (amino acids) from the diet. As a result, affected individuals are not able to use these amino acids to produce other substances, such as vitamins and proteins. Most people with Hartnup disease are able to get the vitamins and other substances they need with a well-balanced diet. People with Hartnup disease have high levels of various amino acids in their urine ( aminoaciduria). For most affected individuals, this is the only sign of the condition. However, some people with Hartnup disease have episodes during which they exhibit other signs, which can include skin rashes; difficulty coordinating movements ( cerebellar ataxia); and psychiatric symptoms, such as depression or psychosis. These episodes are typically temporary and are often triggered by illness, stress, nutrient-poor diet, or fever. These features tend to go away once the trigger is remedied, although the aminoaciduria remains. In affected individuals, signs and symptoms most commonly occur in childhood. Frequency Hartnup disease is estimated to affect 1 in 30,000 individuals. Causes Hartnup disease is caused by mutations in the SLC6A19 gene. This gene provides instructions for making a protein called B0AT1, which is primarily found embedded in the membrane of intestine and kidney cells. The function of this protein is to transport certain amino acids into cells. In the intestines, amino acids from food are transported into intestinal cells then released into the bloodstream so the body can use them. In the kidneys, amino acids are reabsorbed into the bloodstream instead of being removed from the body in urine.
    [Show full text]
  • Diagnosis and Treatment of Tyrosinosis
    Arch Dis Child: first published as 10.1136/adc.43.231.540 on 1 October 1968. Downloaded from Arch. Dis. Childh., 1968, 43, 540. Diagnosis and Treatment of Tyrosinosis ANGELA FAIRNEY, DOROTHY FRANCIS, R. S. ERSSER, J. W. T. SEAKINS, and DENNIS COTTOM From the Department ofChemical Pathology, Institute ofChild Health and The Hospitalfor Sick Children, London W.C.1 This paper describes the diagnosis of tyrosinosis A clean specimen of urine gave a deposit showing scanty in a girl aged 10 months. Her subsequent pro- pus cells, with a mixed growth on culture. X-rays gress after the institution of a diet low in phenyl- showed changes of rickets in the knees and anterior alanine and tyrosine has been good, and details of ends of the ribs and femora. An intravenous pyelogram showed enlarged kidneys with prompt excretion of the her treatment are discussed. dye; there was stretching of the calyces in the left and Tyrosinosis is an inherited metabolic disorder possibly in the right, which was suggestive of the adult characterized by cirrhosis, severe hypophosphat- type of polycystic disease. There was no clear sign of a aemic rickets, renal tubular defects, and a derange- focal lesion or paroxysmal features on the EEG. ment of tyrosine metabolism. The metabolic Biochemical results are listed in Table I. With the products arising from the deranged tyrosine exception of tyrosine, the plasma amino acid pattern metabolism point to a lack of p-hydroxyphenyl- was within the normal range, and in particular methio- pyruvate oxidase (Halvorsen, 1967). nine was never raised (normal approx.
    [Show full text]
  • Antenatal Diagnosis of Inborn Errors Ofmetabolism
    816 ArchivesofDiseaseinChildhood 1991;66: 816-822 CURRENT PRACTICE Arch Dis Child: first published as 10.1136/adc.66.7_Spec_No.816 on 1 July 1991. Downloaded from Antenatal diagnosis of inborn errors of metabolism M A Cleary, J E Wraith The introduction of experimental treatment for Sample requirement and techniques used in lysosomal storage disorders and the increasing prenatal diagnosis understanding of the molecular defects behind By far the majority of antenatal diagnoses are many inborn errors have overshadowed the fact performed on samples obtained by either that for many affected families the best that can amniocentesis or chorion villus biopsy. For be offered is a rapid, accurate prenatal diag- some disorders, however, the defect is not nostic service. Many conditions remain at best detectable in this material and more invasive only partially treatable and as a consequence the methods have been applied to obtain a diagnos- majority of parents seek antenatal diagnosis in tic sample. subsequent pregnancies, particularly for those disorders resulting in a poor prognosis in terms of either life expectancy or normal neurological FETAL LIVER BIOPSY development. Fetal liver biopsy has been performed to The majority of inborn errors result from a diagnose ornithine carbamoyl transferase defi- specific enzyme deficiency, but in some the ciency and primary hyperoxaluria type 1. primary defect is in a transport system or Glucose-6-phosphatase deficiency (glycogen enzyme cofactor. In some conditions the storage disease type I) could also be detected by biochemical defect is limited to specific tissues this method. The technique, however, is inva- only and this serves to restrict the material avail- sive and can be performed by only a few highly able for antenatal diagnosis for these disorders.
    [Show full text]
  • Transporters
    Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2019). The Concise Guide to Pharmacology 2019/20: Transporters. British Journal of Pharmacology, 176(S1), S397-S493. https://doi.org/10.1111/bph.14753 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.14753 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14753. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L Sharman5 , Christopher Southan5 , Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences,
    [Show full text]
  • Metabolic Evaluation of Epilepsy: a Diagnostic Algorithm with Focus on Treatable Conditions
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2018 Metabolic Evaluation of Epilepsy: A Diagnostic Algorithm With Focus on Treatable Conditions van Karnebeek, Clara D M ; Sayson, Bryan ; Lee, Jessica J Y ; Tseng, Laura A ; Blau, Nenad ; Horvath, Gabriella A ; Ferreira, Carlos R Abstract: Although inborn errors of metabolism do not represent the most common cause of seizures, their early identification is of utmost importance, since many will require therapeutic measures beyond that of common anti-epileptic drugs, either in order to control seizures, or to decrease the risk of neurode- generation. We translate the currently-known literature on metabolic etiologies of epilepsy (268 inborn errors of metabolism belonging to 21 categories, with 74 treatable errors), into a 2-tiered diagnostic algo- rithm, with the first-tier comprising accessible, affordable, and less invasive screening tests in urineand blood, with the potential to identify the majority of treatable conditions, while the second-tier tests are ordered based on individual clinical signs and symptoms. This resource aims to support the pediatri- cian, neurologist, biochemical, and clinical geneticists in early identification of treatable inborn errors of metabolism in a child with seizures, allowing for timely initiation of targeted therapy with the potential to improve outcomes. DOI: https://doi.org/10.3389/fneur.2018.01016 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-161470 Journal Article Published Version The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.
    [Show full text]
  • Treatable Inborn Errors of Metabolism Presenting As Cerebral Palsy Mimics
    Leach et al. Orphanet Journal of Rare Diseases 2014, 9:197 http://www.ojrd.com/content/9/1/197 RESEARCH Open Access Treatable inborn errors of metabolism presenting as cerebral palsy mimics: systematic literature review Emma L Leach1,2, Michael Shevell3,4,KristinBowden2, Sylvia Stockler-Ipsiroglu2,5,6 and Clara DM van Karnebeek2,5,6,7,8* Abstract Background: Inborn errors of metabolism (IEMs) have been anecdotally reported in the literature as presenting with features of cerebral palsy (CP) or misdiagnosed as ‘atypical CP’. A significant proportion is amenable to treatment either directly targeting the underlying pathophysiology (often with improvement of symptoms) or with the potential to halt disease progression and prevent/minimize further damage. Methods: We performed a systematic literature review to identify all reports of IEMs presenting with CP-like symptoms before 5 years of age, and selected those for which evidence for effective treatment exists. Results: We identified 54 treatable IEMs reported to mimic CP, belonging to 13 different biochemical categories. A further 13 treatable IEMs were included, which can present with CP-like symptoms according to expert opinion, but for which no reports in the literature were identified. For 26 of these IEMs, a treatment is available that targets the primary underlying pathophysiology (e.g. neurotransmitter supplements), and for the remainder (n = 41) treatment exerts stabilizing/preventative effects (e.g. emergency regimen). The total number of treatments is 50, and evidence varies for the various treatments from Level 1b, c (n = 2); Level 2a, b, c (n = 16); Level 4 (n = 35); to Level 4–5 (n = 6); Level 5 (n = 8).
    [Show full text]